Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a disease that affects over 60 000 people in the UK alone, and around 12 million people worldwide. In this article, Maria Thompson describes the development of a new class of drugs aimed at treating ADPKD, which has been funded in part by Kidney Research UK

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.